Sandur Manganese & Iron Ores Ltd. Share Price

Sandur Manganese Enters Medical Devices Business

The Sandur Manganese & Iron Ores Limited has incorporated Royal Sandur MedTech Private Limited as its wholly owned subsidiary, marking its entry into the medical devices and healthcare consumables manufacturing space. The subsidiary was incorporated in India on September 25, 2026, following the Certificate of Incorporation issued by the Ministry of Corporate Affairs. Royal Sandur MedTech will operate in the medical devices and consumables manufacturing industry. Its proposed business includes manufacturing, processing, assembling, marketing and distribution of medical devices, surgical products, diagnostic products and healthcare consumables. This gives Sandur Manganese exposure to a new business segment beyond its existing operations. The subsidiary is fully owned by The Sandur Manganese & Iron Ores Limited, with 100% of its shareholding held by the listed company. Sandur Manganese has subscribed to 10,00,000 equity shares of ₹10 each, involving a total cash investment of ₹1 crore. The incorporation provides Sandur Manganese with a dedicated platform to develop and participate in the medical products ecosystem. The company has not disclosed, in the filing, details regarding the proposed manufacturing facility, production capacity, specific products to be launched, commercial commencement date or expected revenue contribution from the new subsidiary. For investors, the key factors to monitor going forward will include capital deployment, regulatory requirements applicable to medical devices and diagnostics, manufacturing setup, product launches and the pace of commercialisation. The eventual contribution of Royal Sandur MedTech to the consolidated business will depend on execution and market adoption. The development marks a strategic diversification for Sandur Manganese & Iron Ores, with the company now establishing a presence in medical devices, surgical products, diagnostics and healthcare consumables alongside its existing business operations.

See More

Sandur Manganese Plans New MedTech Subsidiary

Sandur Manganese has approved the incorporation of a wholly owned subsidiary named Royal Sandur MedTech, marking a strategic step towards expanding the company into the medical technology segment. The new subsidiary provides Sandur Manganese with a dedicated platform to explore opportunities in healthcare and medical technology, diversifying its business beyond its existing operations. The MedTech sector offers opportunities across areas such as medical devices, healthcare equipment, diagnostics and other technology-driven solutions, depending on the subsidiary’s eventual business focus. Establishing a wholly owned entity also gives the parent company greater flexibility to develop and scale new initiatives under a separate operating structure. While the incorporation itself is an initial corporate step and may not have an immediate material impact on financial performance, it indicates the company’s intention to explore a new growth avenue. Investors will closely monitor the subsidiary’s proposed activities, investment plans, product development, regulatory approvals and any strategic partnerships that may follow. The eventual financial contribution will depend on how quickly the business is developed and commercialised. For Sandur Manganese, diversification into a new sector could potentially create additional long-term growth opportunities while reducing dependence on its traditional business segments. However, the scale and commercial significance of the new venture will become clearer only as further details regarding operations and investments are announced. Overall, the incorporation of Royal Sandur MedTech represents an early but notable step in Sandur Manganese’s diversification strategy and opens a potential new avenue in the growing healthcare and medical technology ecosystem.

See More

Sandur Manganese & Iron Ores Fundamentals Overview

Sandur Manganese & Iron Ores operates in mining, ferroalloys, coke, energy, and specialty steel. Unlike pure mining companies, it has gradually expanded into integrated operations, giving it better diversification and value addition potential Revenue scale is strong with annual revenue around 4800 to 5000 crore. Growth has been healthy in recent years due to strong iron ore and manganese demand along with expansion into downstream businesses. However, growth remains cyclical because the business is closely tied to commodity prices and mining volumes Profitability is relatively good for a mining company. Net profit has remained healthy and operating leverage becomes strong during favorable commodity cycles. However, margins and earnings fluctuate depending on iron ore and ferroalloy prices, making profit consistency weaker than non cyclical sectors Return ratios are a major strength. Return on equity is around high teens and return on capital employed is also strong, indicating efficient operations and good asset utilization during the current cycle Debt position is comfortable with relatively low leverage, providing balance sheet stability. Promoter holding is also strong and there are no major pledge related concerns One important strength is ownership of iron ore and manganese reserves with long term mining leases, which provides operational visibility and strategic advantage Valuation is moderate. The stock trades at reasonable valuation levels compared to current profitability, but investors should remember that commodity companies often appear cheap near cycle peaks and earnings can decline sharply during downturns Overall, fundamentals are good. The company has strong reserves, decent profitability, healthy return ratios, and a stable balance sheet.

See More

BSE Smallcap Index Plunges Nearly 4% in Brutal Week: Heavy Selling Hammers Multiple Stocks

he BSE Smallcap index endured a punishing week, declining nearly 4% amid broad-based selling pressure across the broader market. The index closed the week around 49,912 levels (as of January 9-10 close), reflecting sharp corrections driven by ongoing foreign institutional investor (FII) outflows, geopolitical uncertainties, and concerns over potential US tariff hikes. Sharp Declines in Key Smallcap Stocks Several smallcap names bore the brunt of the selloff, tumbling between 15% and 23% over the week. Notable losers included: Systematix Corporate Services Balu Forge Industries (which saw intense pressure, with sharp daily drops reported in recent sessions) Worth Investment & Trading !VTM

s !Sai Silks Kalamandir !Indian Metals & Ferro Alloys nd Rectifiers India Stallion India Fluorochemicals Wardwizard Innovations and Mobility Baazar Style Retail eering Company Kitex Garments Faze Three Sandur Manganese and Iron Ores

See More

- Flag breakout trend continuation

has given flag breakout and the stock is continuously making new highs. Stock should have strong support at 240 - 255 with an upside still left

See More